OVERVIEW

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response. Approval of new immune - and target - therapies has further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

ACCREDITATION

CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012). 3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity. Melanoma Bridge Congress has been accredited (ID CME 327- 396007) with 4,2 CME credits with a formative technical-professional objective “Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and Gender medicine”, belonging to formative technical professional objective area, for 201 participants of the following professions: medical doctors, pharmacists, biologists, nurses, pediatric nurses.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order. In order to receive credits, participants must: 1. Attend at least 90% of the accredited CME sessions (attendance check: required sign at the beginning and at the end of works each day); 2. Complete the evaluation form at the end of the Congress. CME certificate will be sent at the end of the validation procedure.

For more information please visit the official event page.